All In Biotech

Drug Trial Radar · NCT04595565

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA

Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,332 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,332

Planned (sponsor's estimate)

Start

Oct 28, 2020

Primary completion

Mar 30, 2027

Study completion Mar 30, 2029

Sponsor

Lead sponsor
GBG Forschungs GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Gilead Sciences; Austrian Breast & Colorectal Cancer Study Group; Spanish Breast Cancer Research Group (GEICAM); ETOP IBCSG Partners Foundation; Cancer Trials Ireland; UNICANCER
First posted
Oct 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy with 1:1 allocation to: * Arm A: Sacituzumab govitecan (days 1, 8 q3w for eight cycles); * Arm B: treatment of physician´s choice (TPC, defined as capecitabine or platinum-based chemotherapy for eight cycles or observation. Treatment in either arm will be given for eight cycles. In patients with HR-positive breast cancer, endocrine-based therapy, which includes the use of CDK4/6 inhibitors, will be administered according to local guidelines. The start of endocrine therapy will be at the discretion of the investigator; however, it will be encouraged to start after surgery/radiotherapy in patients without additional cytotoxic agents. Adjuvant pembrolizumab can be given until the completion of radiotherapy before randomization. Within the study the use of pembrolizumab in patients with TNBC who received pembrolizumab as neoadjuvant therapy is allowed as monotherapy in the TPC arm, according to the approval of pembrolizumab in this setting.

Conditions

  • HER2-negative Breast Cancer
  • Triple Negative Breast Cancer

Interventions

  • CapecitabineDrug

    2000 mg/m² day 1-14 q21 day cycle for eight cycles

  • CarboplatinDrug

    AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles

  • CisplatinDrug

    25mg/m3 weekly or 75 mg/m3 q3w

  • Sacituzumab govitecanDrug

    10 mg/kg body weight on days 1, 8 q3w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice.Time frame: Assuming 3.25 years of recruitment with 12 months ramp-up and 42 patients per month at peak and 3 years of follow-up after the last patient in, 396 events will be needed and final analysis is expected 75 months after study start.

Locations

163 sites in 7 countries. Site status is shown where the registry gives one.

  • MUG - Univ.-Klinik f. Frauenheilkunde u. Geburtshilfe Graz

    Graz, Austria

  • MUG - Univ.-Klinik f. Innere Medizin Graz

    Graz, Austria

  • MUI - Univ. Klinik f. Frauenheilkunde Innsbruck

    Innsbruck, Austria

  • Ordensklinikum Linz GmbH - BHS

    Linz, Austria

  • TumorZentrum Kepler Uniklinikum Linz

    Linz, Austria

  • LKH Salzburg - PMU

    Salzburg, Austria

  • Universitätsklinikum St. Pölten

    Sankt Pölten, Austria

  • MUW - AKH Wien

    Vienna, Austria

  • MUW - Med. Univ.-Klinik AKH Wien

    Vienna, Austria

  • Salzkammergut-Klinikum Vöcklabruck

    Vöcklabruck, Austria

  • Klinikum Wels-Grieskirchen GmbH

    Wels, Austria

  • Landesklinikum Wr. Neustadt

    Wiener Neustadt, Austria

  • CHU UCL Namur/Site Sainte Elisabeth

    Namur, Belgium

  • Institut de cancérologie de l'ouest (Angers)

    Angers, France

  • Institut Sainte Catherine

    Avignon, France

  • Clinique Tivoli Ducos

    Bordeaux, France

  • Institut Bergonié

    Bordeaux, France

  • CH Fleyriat

    Bourg-en-Bresse, France

  • Centre François Baclesse

    Caen, France

  • Centre Jean Perrin 5

    Clermont-Ferrand, France

  • Centre Georges François Leclerc

    Dijon, France

  • Centre Oscar Lambret

    Lille, France

  • CHU de Limoges

    Limoges, France

  • Centre Leon Berard

    Lyon, France

  • Institut Paoli-Calmettes

    Marseille, France

  • Institut régional du Cancer de Montpellier - ICM Val d'Aurelle

    Montpellier, France

  • Hôpital privé du Confluent

    Nantes, France

  • Centre Antoine Lacassagne

    Nice, France

  • Institut Curie (Paris)

    Paris, France

  • Centre Hospitalier de Pau

    Pau, France

  • Hôpital Privé Des Côtes d'Armor- Centre CARIO-HPCA

    Plérin, France

  • Institut Godinot

    Reims, France

  • Centre Eugène Marquis

    Rennes, France

  • Centre Henri Becquerel

    Rouen, France

  • Gcs Rissa

    Sarcelles, France

  • Institut de Cancérologie Strasbourg Europe-ICANS

    Strasbourg, France

  • Institut Claudius Regaud IUCTO

    Toulouse, France

  • CHU Bretonneau

    Tours, France

  • Gustave Roussy Cancer Campus

    Villejuif, France

  • Hämatologie-Onkologie im Zentrum MVZ GmbH

    Augsburg, Germany

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.